Can the HPV Vaccine Prevent Cancer in Boys and Young Men?
Yes. A major study of over 1 million males found that the nine-valent HPV vaccine cut the risk of HPV-related cancers by 46%. The protective effect held across multiple cancer types, including head and neck, esophageal, anal, and penile cancers.
Most people think of HPV vaccination as something for girls. But human papillomavirus causes cancer in men too. This large retrospective study, published in JAMA Oncology, is one of the strongest pieces of evidence yet that vaccinating boys against HPV can prevent cancer later in life.
Dr. Kumar’s Take
I find this study incredibly compelling. We have known for years that HPV causes cancers in both sexes, but the data supporting vaccination in males has lagged behind. This study changes that conversation. With over 1 million participants and up to 10 years of follow-up, the evidence is hard to ignore. A 46% reduction in cancer risk from a safe, widely available vaccine is remarkable. If you have a son, nephew, or young male patient who hasn’t been vaccinated, this data should push that decision forward. HPV vaccination isn’t just about protecting future partners. It’s about protecting the person getting the shot.
How the Study Was Done
Researchers used a large global database to compare boys and young men (ages 9 to 26) who received at least one dose of the nine-valent HPV vaccine with those who were unvaccinated. The study covered the period from January 2016 through December 2024, with outcomes tracked for up to 10 years. Before matching, there were 615,155 vaccinated males and 2,290,623 unvaccinated males. To make the comparison fair, the team used a statistical method called propensity score matching, which created two balanced groups of 510,260 participants each. This helped remove differences in age and other factors that might skew the results.
What the Data Show
The vaccinated group had a significantly lower risk of HPV-related cancers compared to the unvaccinated group, with a hazard ratio of 0.54 (95% CI, 0.37 to 0.81, P = 0.002). In plain terms, vaccinated males were about 46% less likely to develop these cancers. The benefit was consistent across age groups. Boys vaccinated between ages 9 and 14 saw a 42% reduction in cancer risk (HR 0.58, P = 0.04), while those vaccinated between ages 15 and 26 saw a 50% reduction (HR 0.50, P = 0.03). The cancers tracked included head and neck cancers, esophageal cancer, anal cancer, and penile cancer, all of which are linked to HPV infection.
Why This Matters for Cancer Prevention
HPV-related cancers in men are rising, especially head and neck cancers. Yet HPV vaccination rates in males remain lower than in females in many countries. This study provides strong real-world evidence that the vaccine works as a cancer prevention tool for males, not just as a way to reduce transmission to female partners. The findings support what many public health experts have been calling for: sex-neutral vaccination programs that treat boys and girls equally when it comes to HPV protection.
Safety and Limitations
The study did not report serious safety concerns with the vaccine. However, there are some important limitations to keep in mind. This was a retrospective study, not a randomized controlled trial, so it cannot prove cause and effect with absolute certainty. The propensity score matching helps, but there may be unmeasured differences between the two groups. Also, the follow-up period of up to 10 years is relatively short for studying cancers that can take decades to develop. Longer-term data will strengthen the case even further.
Practical Takeaways
- If you have a son or young male family member between ages 9 and 26 who hasn’t received the HPV vaccine, talk to their doctor about starting the series now, as earlier vaccination appears to offer strong protection.
- The HPV vaccine protects males against multiple cancer types, including head and neck, esophageal, anal, and penile cancers, so it is not just about reproductive health.
- Even if your son is already a teenager, the data shows significant cancer risk reduction for those vaccinated between ages 15 and 26, so it is not too late.
Related Studies and Research
- Exercise after breast cancer could cut your death risk by up to 37% looks at another powerful cancer prevention strategy through physical activity.
- Why your metabolism may matter more than your weight for cancer risk explores the metabolic factors that influence cancer development.
- Obesity doubles GERD risk: meta-analysis of 57,000 patients examines how body weight affects esophageal health, a region also impacted by HPV-related cancers.
- H. pylori protects against Barrett’s esophagus: meta-analysis covers another infectious agent with surprising effects on cancer risk in the upper digestive tract.
FAQs
At what age should boys get the HPV vaccine?
The CDC recommends starting the HPV vaccine series at age 11 or 12, though it can be given as early as age 9. This study found strong protection in boys vaccinated between ages 9 and 14, with a 42% reduction in cancer risk. Starting early allows the immune system to build a robust response before any potential HPV exposure. If your son missed the recommended window, catch-up vaccination is available through age 26 and still showed a 50% cancer risk reduction in this study.
Does the HPV vaccine only prevent cervical cancer?
No. While the HPV vaccine was originally developed and promoted for cervical cancer prevention in women, HPV causes cancers throughout the body in both sexes. In males, HPV is linked to head and neck cancers (especially oropharyngeal cancer, which is rising sharply), anal cancer, penile cancer, and esophageal cancer. Head and neck cancers caused by HPV have actually overtaken cervical cancer in incidence in some countries. The nine-valent vaccine targets the HPV strains responsible for the vast majority of these cancers.
How many doses of the HPV vaccine are needed?
For children who start the series before age 15, two doses given 6 to 12 months apart are typically sufficient. Those who begin at age 15 or older need three doses over a six-month period. This study included males who received at least one dose, and the protective effect was already apparent. However, completing the full series as recommended gives the best chance of long-term protection. Talk to your doctor about the right schedule based on your age and health history.
Bottom Line
This study of over 1 million males provides strong evidence that the nine-valent HPV vaccine reduces the risk of HPV-related cancers by 46% in boys and young men. The protection extends across head and neck, esophageal, anal, and penile cancers, and it works whether vaccination happens in childhood or young adulthood. HPV vaccination is not just for girls. It is a proven cancer prevention strategy for males too.
